BioCentury
ARTICLE | Clinical News

Alagebrium: Phase IIa data

November 21, 2005 8:00 AM UTC

In the open-label, U.S. Phase IIa PEDESTAL trial in 22 patients, alagebrium led to the regression of left ventricular mass (p=0.002) and left ventricular end-diastolic volume. As measured by Doppler e...